

Resource Summary Report

Generated by [NIF](#) on Aug 22, 2026

Brilliant Violet 510(TM) anti-human CD19

RRID:AB_2561668

Type: Antibody

Proper Citation

BioLegend Cat# 302242, RRID:AB_2561668

Antibody Information

URL: http://antibodyregistry.org/AB_2561668

Proper Citation: BioLegend Cat# 302242, RRID:AB_2561668

Target Antigen: CD19

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 510(TM) anti-human CD19

Description: This monoclonal targets CD19

Target Organism: human

Clone ID: Clone HIB19

Antibody ID: AB_2561668

Vendor: BioLegend

Catalog Number: 302242

Alternative Catalog Numbers: 302241

Record Creation Time: 20250820T003622+0000

Record Last Update: 20250820T084321+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 510(TM) anti-human CD19.

No alerts have been found for Brilliant Violet 510(TM) anti-human CD19.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 49 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Matei DE, et al. (2026) Sexual dimorphism of early GPR183-dependent B cell responses in systemic lupus erythematosus. *iScience*, 29(3), 114980.

Ma J, et al. (2026) Paired pre- and post-transplant human immunoprofiling identifies an IFN- γ -JAK1 axis limiting stem-cell-derived RPE engraftment. *Cell stem cell*, 33(7), 1127.

La C, et al. (2026) In vivo modeling of human $\gamma\delta$ T cell ontogeny reveals terminal deoxynucleotidyl transferase as a key regulator of type 3 V δ 2 T cell development. *Cell reports*, 45(2), 116977.

Rollin P, et al. (2026) BCG immunotherapy for bladder cancer triggers systemic and local BCG-specific CD4⁺ Th1 responses. *iScience*, 29(2), 114676.

Li S, et al. (2026) Lung mucosal and systemic responses at single-cell resolution in an aerosolized *Mycobacterium bovis* BCG human challenge model. *Cell reports. Medicine*, 7(6), 102830.

Van Laethem JL, et al. (2025) CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. *Cell reports. Medicine*, 6(10), 102407.

Conti A, et al. (2025) Senescence and inflammation are unintended adverse consequences of CRISPR-Cas9/AAV6-mediated gene editing in hematopoietic stem cells. *Cell reports. Medicine*, 6(6), 102157.

Chu Q, et al. (2025) Efficient boosting of Omicron-reactive memory B cells after breakthrough infection protects from repeated exposure. *iScience*, 28(4), 112278.

Martínez-Balboa Y, et al. (2025) Age and primary vaccination schedule impact humoral and cellular immunity with an inactivated SARS-CoV-2 vaccine. *iScience*, 28(8), 113167.

Della Volpe L, et al. (2025) Protocol for optimizing culture conditions for ex vivo activation during CRISPR-Cas9 gene editing in human hematopoietic stem and progenitor cells. *STAR protocols*, 6(2), 103722.

Rao VN, et al. (2025) Clonotype-enriched somatic hypermutations drive affinity maturation of a public human antibody targeting an occluded sarbecovirus epitope. *Cell reports*, 44(8), 116122.

Arbués A, et al. (2025) Soluble immune mediators orchestrate protective in vitro granulomatous responses across *Mycobacterium tuberculosis* complex lineages. *eLife*, 13.

Ahn JJ, et al. (2025) Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity. *Cell reports. Medicine*, 6(8), 102257.

Dingus J, et al. (2025) Affinity maturation and light-chain-mediated paratope diversification anticipates viral evolution. *Cell reports*, 45(1), 116800.

Müller TR, et al. (2024) Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant. *Cell host & microbe*, 32(2), 156.

Della Volpe L, et al. (2024) A p38 MAPK-ROS axis fuels proliferation stress and DNA damage during CRISPR-Cas9 gene editing in hematopoietic stem and progenitor cells. *Cell reports. Medicine*, 5(11), 101823.

Padoan B, et al. (2024) NKp44/HLA-DP-dependent regulation of CD8 effector T cells by NK cells. *Cell reports*, 43(4), 114089.

Reid KT, et al. (2024) Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses. *Cell reports*, 44(1), 115102.

Pelletier AN, et al. (2024) A pre-vaccination immune metabolic interplay determines the protective antibody response to a dengue virus vaccine. *Cell reports*, 43(7), 114370.

Adamo S, et al. (2023) Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox. *Cell host & microbe*, 31(6), 928.